Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KIF11 | P52732 | 5/20 | 0.54 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.46 |
| ▸ | ACLY | P53396 | 1/20 | 0.45 |
| ▸ | BCHE | P06276 | 1/20 | 0.43 |
| ▸ | ACHE | P22303 | 1/20 | 0.43 |
| ▸ | PARP14 | Q460N5 | 1/20 | 0.42 |
| ▸ | CA1 | P00915 | 2/20 | 0.42 |
| ▸ | CA2 | P00918 | 2/20 | 0.42 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.41 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.41 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.41 |
| ▸ | SRD5A2 | P31213 | 1/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24425798 | 0.86 | KIF11 (0.51) | KIF11KMT2AACLYBCHEACHE | |
| SCHEMBL3489476 | 0.84 | KIF11 (0.53) | KIF11KMT2AACLYBCHEACHE | |
| SCHEMBL16914883 | 0.81 | CA1 (0.58) | KIF11KMT2AACLYPARP14CA1 | |
| SCHEMBL341095 | 0.81 | PPARG (0.41) | KIF11ACLY | |
| SCHEMBL18571239 | 0.81 | KIF11 (0.50) | KIF11KMT2AACLYBCHEACHE | |
| SCHEMBL10154100 | 0.80 | GALR3 (0.54) | KMT2ACA1CA2TAAR1CYP19A1 | |
| SCHEMBL10153979 | 0.79 | KMT2A (0.53) | KMT2ABCHEACHECA1CA2 | |
| SCHEMBL2375558 | 0.79 | KIF11 (0.59) | KIF11KMT2ABCHEACHECA1 | |
| SCHEMBL26212936 | 0.77 | KIF11 (0.50) | KIF11KMT2AACLYPARP14CA1 | |
| SCHEMBL18571400 | 0.77 | PTPRZ1 (0.51) | KIF11CA1CA2ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2485591-B1 | IMINOTHIADIAZINE DIOXIDE COMPOUNDS AS BACE INHIBITORS, COMPOSITIONS, AND THEIR USE | MERCK SHARP & DOHME (US) | 2016-03-23 | — | — | EP | disclosed |
| EP-2485591-B1 | IMINOTHIADIAZINE DIOXIDE COMPOUNDS AS BACE INHIBITORS, COMPOSITIONS, AND THEIR USE | MERCK SHARP & DOHME (US) | 2016-03-23 | — | — | EP | disclosed |
| US-8563543-B2 | Iminothiadiazine dioxide compounds as bace inhibitors, compositions, and their use | MERCK SHARP & DOHME CORP. (US) | 2013-10-22 | — | — | US | disclosed |
| US-8563543-B2 | Iminothiadiazine dioxide compounds as bace inhibitors, compositions, and their use | MERCK SHARP & DOHME CORP. (US) | 2013-10-22 | — | — | US | disclosed |
| US-8563543-B2 | Iminothiadiazine dioxide compounds as bace inhibitors, compositions, and their use | MERCK SHARP & DOHME CORP. (US) | 2013-10-22 | — | — | US | disclosed |
| EP-2485591-A1 | IMINOTHIADIAZINE DIOXIDE COMPOUNDS AS BACE INHIBITORS, COMPOSITIONS, AND THEIR USE | Merck Sharp & Dohme Corp. (US) | 2012-08-15 | — | — | EP | disclosed |
| US-20120189642-A1 | IMINOTHIADIAZINE DIOXIDE COMPOUNDS AS BACE INHIBITORS, COMPOSITIONS, AND THEIR USE | SCHERING CORPORATION (US) | 2012-07-26 | — | — | US | disclosed |
| US-20120189642-A1 | IMINOTHIADIAZINE DIOXIDE COMPOUNDS AS BACE INHIBITORS, COMPOSITIONS, AND THEIR USE | SCHERING CORPORATION (US) | 2012-07-26 | — | — | US | disclosed |
| US-20120189642-A1 | IMINOTHIADIAZINE DIOXIDE COMPOUNDS AS BACE INHIBITORS, COMPOSITIONS, AND THEIR USE | SCHERING CORPORATION (US) | 2012-07-26 | — | — | US | disclosed |
| US-20120165309-A1 | HETERO RING DERIVATIVE | ASTELLAS PHARMA INC. (JP) | 2012-06-28 | — | — | US | disclosed |
| EP-2397479-A1 | HETERO RING DERIVATIVE | Astellas Pharma Inc. (JP) | 2011-12-21 | — | — | EP | disclosed |
| WO-2011044187-A1 | IMINOTHIADIAZINE DIOXIDE COMPOUNDS AS BACE INHIBITORS, COMPOSITIONS, AND THEIR USE | SCHERING CORPORATION (US) | 2011-04-14 | — | — | WO | disclosed |
| WO-2010092962-A1 | HETERO RING DERIVATIVE | アステラス製薬株式会社 (JP) | 2010-08-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120165309-A1 | HETERO RING DERIVATIVE | IL2, PIK3R2, IL2RA | KIF11 4857/4885KMT2A 1656/4885ACLY 4481/4885 |
| US-20120189642-A1 | IMINOTHIADIAZINE DIOXIDE COMPOUNDS AS BACE INHIBITORS, COMPOSITIONS, AND THEIR USE | BACE1, APP, BACE2 | KIF11 4434/4885KMT2A 2560/4885ACLY 3438/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.